Semaglutide and SNAC levels in breast milk are being investigated in healthy, breastfeeding women.

Type 2 diabetes and obesity are chronic conditions with increasing global prevalence, often requiring sustained pharmacological intervention. Semaglutide, a potent GLP-1 receptor agonist, has emerged as a highly effective treatment for these conditions, available in both injectable and oral formulations. While its efficacy and safety profile are well-established in the general population, critical data regarding its pharmacokinetics and potential transfer into breast milk during lactation are conspicuously absent. This significant knowledge gap poses a challenge for healthcare providers and breastfeeding mothers, who currently lack evidence-based guidance on the potential for infant exposure to semaglutide via breast milk. Understanding this drug transfer is paramount to ensure both maternal health management and infant safety, addressing a crucial unmet need in clinical practice.